William Chou
Chief Executive Officer chez PASSAGE BIO, INC.
Fortune : - $ au 31/03/2024
Profil
William Chou is currently the President, Chief Executive Officer & Director at Passage Bio, Inc. Prior to his current position, he served as the Chief Executive Officer at Aruvant Sciences, Inc. Dr. Chou completed his undergraduate degree at Princeton University, followed by an MBA from Yale School of Management.
He also holds a doctorate degree from the University of Pittsburgh School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PASSAGE BIO, INC.
-.--% | 18/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de William Chou
| Sociétés | Poste | Début |
|---|---|---|
| PASSAGE BIO, INC. | Chief Executive Officer | 10/10/2022 |
Anciens postes connus de William Chou
| Sociétés | Poste | Fin |
|---|---|---|
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Chief Executive Officer | - |
Formation de William Chou
| Princeton University | Undergraduate Degree |
| Yale School of Management | Masters Business Admin |
| University of Pittsburgh School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PASSAGE BIO, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
